Gossamer Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GOSS Nasdaq 2836 www.gossamerbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Gossamer Bio, Inc.

Analysts Remain Bullish on Gossamer Bio (GOSS) Despite Phase 3 Setback - Apr 12th, 2026 3:47 pm
Cantor Fitzgerald Downgrades Gossamer Bio (GOSS) to Neutral - Apr 7th, 2026 8:30 am
Why Bullish Analysts Still See Major Upside in Gossamer Bio (GOSS) After PROSERA Setback - Mar 30th, 2026 12:23 am
Gossamer Bio (GOSS) Continues Downtrend Despite Impressive Revenue - Mar 24th, 2026 3:46 pm
Analysts Revise Forecasts for Gossamer Bio (GOSS) Amid Uncertain Regulatory Environment - Mar 20th, 2026 1:16 pm
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates - Mar 17th, 2026 3:10 pm
Gossamer Bio: Q4 Earnings Snapshot - Mar 17th, 2026 2:08 pm
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update - Mar 17th, 2026 2:01 pm
Gossamer Bio options imply 46.1% move in share price post-earnings - Mar 13th, 2026 11:35 am
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Mar 9th, 2026 8:00 am
How The Gossamer Bio (GOSS) Story Is Shifting After PROSERA And New Street Valuations - Mar 9th, 2026 2:09 am
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1 - Mar 7th, 2026 4:46 am
Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline - Mar 5th, 2026 8:00 am
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates - Feb 26th, 2026 10:15 am
Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now - Feb 26th, 2026 7:55 am
Gossamer Bio (GOSS) Loses 85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Feb 26th, 2026 7:35 am
BC-Most Active Stocks - Feb 25th, 2026 8:30 am
Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension - Feb 25th, 2026 3:51 am
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates - Feb 24th, 2026 7:40 am
Qualcomm, Booking Holdings upgraded: Wall Street's top analyst calls - Feb 24th, 2026 7:39 am